- Home
- ACLX vs PRCT Comparison
ACLX vs PRCT Comparison
Compare ACLX & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- PRCT
- Stock Information
- Founded
- ACLX 2015
- PRCT 2009
- Country
- ACLX United States
- PRCT United States
- Employees
- ACLX N/A
- PRCT N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- PRCT Medical Specialities
- Sector
- ACLX Health Care
- PRCT Health Care
- Exchange
- ACLX Nasdaq
- PRCT Nasdaq
- Market Cap
- ACLX 4.1B
- PRCT 2.1B
- IPO Year
- ACLX 2022
- PRCT 2021
- Fundamental
- Price
- ACLX $78.49
- PRCT $37.61
- Analyst Decision
- ACLX Strong Buy
- PRCT Buy
- Analyst Count
- ACLX 13
- PRCT 8
- Target Price
- ACLX $114.75
- PRCT $70.00
- AVG Volume (30 Days)
- ACLX 507.4K
- PRCT 962.8K
- Earning Date
- ACLX 11-06-2025
- PRCT 10-27-2025
- Dividend Yield
- ACLX N/A
- PRCT N/A
- EPS Growth
- ACLX N/A
- PRCT N/A
- EPS
- ACLX N/A
- PRCT N/A
- Revenue
- ACLX $56,979,000.00
- PRCT $274,950,000.00
- Revenue This Year
- ACLX N/A
- PRCT $48.38
- Revenue Next Year
- ACLX $174.18
- PRCT $30.87
- P/E Ratio
- ACLX N/A
- PRCT N/A
- Revenue Growth
- ACLX N/A
- PRCT 55.71
- 52 Week Low
- ACLX $47.86
- PRCT $36.90
- 52 Week High
- ACLX $107.37
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- ACLX 64.42
- PRCT 41.20
- Support Level
- ACLX $73.16
- PRCT $36.90
- Resistance Level
- ACLX $79.49
- PRCT $40.10
- Average True Range (ATR)
- ACLX 2.83
- PRCT 1.85
- MACD
- ACLX 0.58
- PRCT 0.35
- Stochastic Oscillator
- ACLX 88.07
- PRCT 14.92
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.